The past two years have brought a wave of FDA-cleared AI tools to radiology departments across the country. From chest X-ray triage to CT pulmonary embolism detection, the technology is no longer theoretical — it is showing up in worklists, hanging protocols, and departmental budgets. But adoption is fragmented, and many radiologists are still figuring out how to integrate these tools into daily practice without compromising speed, accuracy, or liability.

How AI Tools Are Actually Being Used Today

Most deployed AI systems in radiology fall into one of three categories: worklist prioritization, incidental finding flagging, and measurement automation. Worklist triage tools — which push potentially critical studies to the top of the queue — have seen the broadest adoption, particularly in emergency settings where stroke and hemorrhage detection tools have demonstrated meaningful reductions in time-to-read. Incidental finding tools, such as those that automatically flag pulmonary nodules on routine chest CTs, are gaining ground but raise new questions about workflow integration and follow-up responsibility. Measurement automation, including bone age estimation and vertebral fracture detection, is proving popular for high-volume subspecialty work where repetitive tasks slow throughput.

The Liability Question Nobody Wants to Answer

As AI tools move from optional add-ons to embedded features in PACS platforms, a pressing question is crystallizing: when an AI tool misses a finding and the radiologist does too, who is responsible? Legal precedent here is thin. Current consensus — from professional societies and malpractice carriers alike — is that the radiologist retains full interpretive responsibility regardless of what an AI tool did or did not flag. In practice, this means AI is functioning as a second reader without actually reducing accountability. That dynamic creates a real cognitive burden: some radiologists report spending additional time second-guessing their reads when AI outputs are present, particularly when the AI's result conflicts with their own impression.

What to Look for When Evaluating AI Vendors

Not all FDA-cleared AI tools are created equal, and clearance alone does not guarantee clinical utility. When evaluating a new product, radiology departments should be asking for validation data from institutions with comparable patient demographics and imaging equipment — performance on a curated academic dataset does not always translate to a community hospital environment. Transparency about false positive rates is equally important; a tool with high sensitivity but poor specificity can generate alert fatigue that ultimately degrades workflow rather than improving it. Finally, ask whether the vendor provides post-deployment monitoring. AI models can drift as scanner hardware, imaging protocols, and patient populations change over time, and ongoing performance tracking is increasingly considered a best practice rather than a bonus feature.

Articles

AI-Assisted Imaging Interpretation: What Radiologists Need to Know in 2026